{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:33:04Z","timestamp":1770885184821,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Guerbet, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Radiol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00247-020-04626-z","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T07:03:45Z","timestamp":1581577425000},"page":"855-862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety of gadoterate meglumine in children younger than 2\u00a0years of age"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0225-6291","authenticated-orcid":false,"given":"Shannon G.","family":"Farmakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamsheldeen Y.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Wilson-Flewelling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting Y.","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"4626_CR1","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3109\/02841851.2010.515614","volume":"51","author":"D Xia","year":"2010","unstructured":"Xia D, Davis RL, Crawford JA, Abraham JL (2010) Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Acta Radiol 51:1126\u20131136","journal-title":"Acta Radiol"},{"key":"4626_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1148\/radiol.15150025","volume":"275","author":"RJ McDonald","year":"2015","unstructured":"McDonald RJ, McDonald JS, Kallmes DF et al (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275:772\u2013782","journal-title":"Radiology"},{"key":"4626_CR3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1148\/radiol.13131669","volume":"270","author":"T Kanda","year":"2014","unstructured":"Kanda T, Ishii K, Kawaguchi H et al (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834\u2013841","journal-title":"Radiology"},{"key":"4626_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.2015142690","volume":"276","author":"T Kanda","year":"2015","unstructured":"Kanda T, Fukusato T, Matsuda M et al (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276:228\u2013232","journal-title":"Radiology"},{"key":"4626_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1148\/radiol.14140364","volume":"275","author":"T Kanda","year":"2015","unstructured":"Kanda T, Osawa M, Oba H et al (2015) High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 275:803\u2013809","journal-title":"Radiology"},{"key":"4626_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/01.rli.0000186569.32408.95","volume":"41","author":"GW White","year":"2006","unstructured":"White GW, Gibby WA, Tweedle MF (2006) Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (Prohance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Investig Radiol 41:272\u2013278","journal-title":"Investig Radiol"},{"key":"4626_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1148\/radiol.2016152846","volume":"281","author":"N Maximova","year":"2016","unstructured":"Maximova N, Gregori M, Zennaro F et al (2016) Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology 281:418\u2013426","journal-title":"Radiology"},{"key":"4626_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1148\/radiol.2016160356","volume":"282","author":"TF Flood","year":"2017","unstructured":"Flood TF, Stence NV, Maloney JA, Mirsky DM (2017) Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. Radiology 282:222\u2013228","journal-title":"Radiology"},{"key":"4626_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/jmri.25625","volume":"46","author":"TJ Fraum","year":"2017","unstructured":"Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ (2017) Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging 46:338\u2013353","journal-title":"J Magn Reson Imaging"},{"key":"4626_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/RLI.0000000000000462","volume":"53","author":"J Endrikat","year":"2018","unstructured":"Endrikat J, Dohanish S, Schleyer N et al (2018) 10 years of nephrogenic systemic fibrosis: a comprehensive analysis of nephrogenic systemic fibrosis reports received by a pharmaceutical company from 2006 to 2016. Investig Radiol 53:541\u2013550","journal-title":"Investig Radiol"},{"key":"4626_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1148\/radiol.2017162740","volume":"286","author":"AH Behzadi","year":"2018","unstructured":"Behzadi AH, Zhao Y, Farooq Z, Prince MR (2018) Immediate allergic reactions to gadoliniums-based contrast agents: a systematic review and meta-analysis. Radiology 286:471\u2013482","journal-title":"Radiology"},{"key":"4626_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/RLI.0000000000000276","volume":"51","author":"E de Kerviler","year":"2016","unstructured":"de Kerviler E, Maravilla K, Meder JF et al (2016) Adverse reactions to gadoterate meglumine: review of over 25 years of clinical use and more than 50 million doses. Investig Radiol 51:544\u2013551","journal-title":"Investig Radiol"},{"key":"4626_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1148\/radiol.2019182834","volume":"292","author":"JS McDonald","year":"2019","unstructured":"McDonald JS, Hunt CH, Kolbe AB et al (2019) Acute adverse events following gadolinium-based contrast agent administration: a single-center retrospective study of 281,945 injections. Radiology 292:620\u2013627","journal-title":"Radiology"},{"key":"4626_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10534-008-9135-x","volume":"21","author":"M Port","year":"2008","unstructured":"Port M, Id\u00e9e JM, Medina C et al (2008) Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 21:469\u2013490","journal-title":"Biometals"},{"key":"4626_CR15","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/jmri.21967","volume":"30","author":"JM Id\u00e9e","year":"2009","unstructured":"Id\u00e9e JM, Port M, Robic C et al (2009) Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 30:1249\u20131258","journal-title":"J Magn Reson Imaging"},{"key":"4626_CR16","unstructured":"Guerbet LLC (2018) Dotarem (gadoterate meglumine) [package insert]. Princeton"},{"key":"4626_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0952-8180(94)00001-K","volume":"7","author":"JA Aldrete","year":"1995","unstructured":"Aldrete JA (1995) The post-anesthesia recover score revisited. J Clin Anesth 7:89\u201391","journal-title":"J Clin Anesth"},{"key":"4626_CR18","unstructured":"American College of Radiology (2018) ACR Manual on Contrast Media. Version 10.3. https:\/\/www.acr.org\/ClinicalResources\/Contrast-Manual. Accessed 25 Sept 2019"},{"key":"4626_CR19","unstructured":"Microsoft (2016) Excel Version 1.5 [computer software]"},{"key":"4626_CR20","unstructured":"Maple Tech International, LLC (2008\u20132019). Calculator.net [computer software]. https:\/\/www.calculator.net\/standard-deviation-calculator.html. Accessed 25 Sept 2019"},{"key":"4626_CR21","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1007\/s00247-018-4241-6","volume":"48","author":"JR Dillman","year":"2018","unstructured":"Dillman JR, Trout AT, Davenport MS (2018) Allergic-like contrast media reaction management in children. Pediatr Radiol 48:1688\u20131694","journal-title":"Pediatr Radiol"},{"key":"4626_CR22","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2214\/AJR.06.1328","volume":"188","author":"JR Dillman","year":"2007","unstructured":"Dillman JR, Strouse PJ, Ellis JH et al (2007) Incidence and severity of acute allergic-like reactions to i.v. nonionic iodinated contrast material in children. AJR Am J Roentgenol 188:1643\u20131647","journal-title":"AJR Am J Roentgenol"},{"key":"4626_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1148\/radiology.175.3.2343107","volume":"175","author":"H Katayama","year":"1990","unstructured":"Katayama H, Yamaguchi K, Kozuka T et al (1990) Adverse reactions to ionic and nonionic contrast media: a report from the Japanese committee on the safety of contrast media. Radiology 175:621\u2013628","journal-title":"Radiology"},{"key":"4626_CR24","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2214\/AJR.07.2554","volume":"189","author":"JR Dillman","year":"2007","unstructured":"Dillman JR, Ellis JH, Cohan RH et al (2007) Frequency and severity of acute allergic-like reactions to gadolinium-containing I.V. contrast media in children and adults. AJR Am J Roentgenol 189:1533\u20131538","journal-title":"AJR Am J Roentgenol"},{"key":"4626_CR25","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1177\/0284185119840649","volume":"60","author":"DH Chang","year":"2019","unstructured":"Chang DH, Pracros JP (2019) Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study. Acta Radiol 60:1450\u20131456","journal-title":"Acta Radiol"},{"key":"4626_CR26","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00247-015-3394-9","volume":"45","author":"C Balassy","year":"2015","unstructured":"Balassy C, Roberts D, Miller SF (2015) Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies. Pediatr Radiol 45:1831\u20131841","journal-title":"Pediatr Radiol"},{"key":"4626_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ejrad.2011.04.022","volume":"81","author":"M Maurer","year":"2012","unstructured":"Maurer M, Heine O, Wolf M et al (2012) Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: result in more than 84,000 patients. Eur J Radiol 81:885\u2013890","journal-title":"Eur J Radiol"},{"key":"4626_CR28","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00247-011-2167-3","volume":"41","author":"S Emond","year":"2011","unstructured":"Emond S, Brunelle F (2011) Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions. Pediatr Radiol 41:1401\u20131406","journal-title":"Pediatr Radiol"},{"key":"4626_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/RLI.0000000000000412","volume":"53","author":"M Scala","year":"2018","unstructured":"Scala M, Koob M, de Buttet S et al (2018) A pharmacokinetics, efficacy, and safety study of gadoterate meglumine in pediatric subjects aged younger than 2 years. Investig Radiol 53:70\u201379","journal-title":"Investig Radiol"},{"key":"4626_CR30","unstructured":"Briand Y, Neiss AC, Vitry A (1992) Efficacy and safety of the macrocyclic complex Gd-DOTA in children: results of a multi-Centre study. Proceedings of the 29th congress of the European Society of Pediatric Radiology, 128"},{"key":"4626_CR31","first-page":"383","volume":"3","author":"AC Neiss","year":"1991","unstructured":"Neiss AC, Le Mignon MM, Vitry A, Caille JM (1991) Efficacy and safety of DOTA-Gd from a European multicenter survey. Rev Im Med 3:383\u2013387","journal-title":"Rev Im Med"},{"key":"4626_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2165\/11539140-000000000-00000","volume":"10","author":"T Ishiguchi","year":"2010","unstructured":"Ishiguchi T, Takahashi S (2010) Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D 10:133\u2013145","journal-title":"Drugs R D"},{"key":"4626_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/RLI.0000000000000444","volume":"53","author":"MM Forbes-Amrhein","year":"2018","unstructured":"Forbes-Amrhein MM, Dillman JR et al (2018) Frequency and severity of acute allergic-like reactions to intravenously administered gadolinium-based contrast media in children. Investig Radiol 53:313\u2013318","journal-title":"Investig Radiol"},{"key":"4626_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4097\/kjae.2010.59.4.275","volume":"59","author":"WJ Choi","year":"2010","unstructured":"Choi WJ, Choi SI, Mok JM et al (2010) Recurrent unilateral lung ventilation disorder in a patient that experienced rocuronium-induced anaphylactic bronchospasm during laparoscopic rectal surgery. Korean J Anesthesiol 59:275\u2013278","journal-title":"Korean J Anesthesiol"},{"key":"4626_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13497413.2018.1481580","volume":"41","author":"Y Morimoto","year":"2018","unstructured":"Morimoto Y, Satake S, Kamitani A et al (2018) Rocuronium anaphylaxis in a 7-year-old boy during the induction of anesthesia. Immunol Med 41:85\u201388","journal-title":"Immunol Med"},{"key":"4626_CR36","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3349\/ymj.2013.54.3.732","volume":"54","author":"JM Kim","year":"2013","unstructured":"Kim JM, Lee JH, Lee HJ, Koo BN (2013) Comparison of emergence time in children undergoing minor surgery according to anesthetic: desflurane and sevoflurance. Yonsei Med J 54:732\u2013738","journal-title":"Yonsei Med J"},{"key":"4626_CR37","first-page":"e9661","volume":"97","author":"N Bedirli","year":"2018","unstructured":"Bedirli N, I\u015fik B, Bashiri M et al (2018) Clinically suspected anaphylaxis induced by sugammadex in a patient with weaver syndrome undergoing restrictive mammoplasty surgery. Clin Case Report 97:e9661","journal-title":"Clin Case Report"},{"key":"4626_CR38","first-page":"66","volume":"46","author":"A \u00c7olak","year":"2018","unstructured":"\u00c7olak A, Yilmaz E, Kiray BK (2018) Sugammadex-induced hypersensitivity reaction in a pediatric patient. Turk J Anaesthesiol Reanim 46:66\u201368","journal-title":"Turk J Anaesthesiol Reanim"},{"key":"4626_CR39","unstructured":"Maruishi Pharmaceutical Company. Ultane (sevoflurane) [package insert]. U.S. Food and Drug Administration website. Revised April 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020478s030lbl.pdf. Accessed 16 Dec 2019"},{"key":"4626_CR40","unstructured":"Merck & Co., Inc. (2015) Bridion (sugammadex) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022225lbl.pdf. Accessed 16 Dec 2019"},{"key":"4626_CR41","unstructured":"Teva Pharmaceutical Ind. Ltd. (2008) Rocuronium bromide [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/078717s000lbl.pdf. Accessed 16 Dec 2019"},{"key":"4626_CR42","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1080\/02841850802282811","volume":"49","author":"AF Kopp","year":"2008","unstructured":"Kopp AF, Mortele KJ, Cho YD et al (2008) Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients. Acta Radiol 49:902\u2013911","journal-title":"Acta Radiol"}],"container-title":["Pediatric Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00247-020-04626-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00247-020-04626-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00247-020-04626-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:28:58Z","timestamp":1613089738000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00247-020-04626-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4626"],"URL":"https:\/\/doi.org\/10.1007\/s00247-020-04626-z","relation":{},"ISSN":["0301-0449","1432-1998"],"issn-type":[{"value":"0301-0449","type":"print"},{"value":"1432-1998","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"29 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Farmakis has research grants from GE Healthcare and Guerbet, LLC, and is a consultant for GE Precision Healthcare, LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}